Biocon Biologics Partners with Sandoz Australia for Biosimilars

Biocon Biologics, a subsidiary of Biocon, has now entered into a five-year agreement with Sandoz AG, which allows Sandoz to promote, sell and distribute the A$35 million market value biosimilar Trastuzumab and the biosimilar Bevacizumab. Market worth A$45 million in Australia.

Under this agreement, Sandoz will distribute the Biocon Biologics brands of Ogivri (Trastuzumab) and Abevmy (Bevacizumab), allowing continued access to these drugs already distributed by other pharmaceutical companies to Australian patients. Trastuzumab is a biologic of Herceptin and Bevacizumab is a biologic of Avastin. Both biologics are available on PBS and are used to treat various cancers.

This contract will be effective from January 1, 2024, and commercialization will begin on February 1, 2024. The agreement with Sandoz in Japan and Australia is another milestone in our partnership with the growth strategy. This partnership also plays an important role for Australian patients, ensuring continued access to affordable, high-quality biologics in oncology.